Recent results have demonstrated that the spin trapping agent a-phenyl-N-tert-butyl nitrone (PBN) reduces in farct volume in rats subjected to 2 hours of middle cerebral artery occlusion, even when given 1 to 3 hours after the start of recirculation. In the current study, the authors assessed the effect of NXY-059, a novel nitrone that is more soluble than PBN. Loading doses were given of 0.30, 3.0, or 30 mg , kg-l followed by 0.30, 3.0, or 30 mg . kg-I . h-1 for 24 or 48 hours. Dose-response studies showed that when treatment was begun I hour after recirculation, 0.30 mg . kg-l had a small and 30 mg . kg-l a marked effect on infarct volume. At equimolar doses (3.0 mg . kg-lfor NXY-059 and 1.4 mg . kg-l for PBN),
A spin trap nitrone, a-phenyl-N-tert-butyl nitrone (PBN), has previously been shown to ameliorate isch emic brain damage. The original observations were made in gerbils subjected to 5 to 10 minutes of forebrain isch emia (Oliver et aI., 1990; Phillis and Clough-Helfman, 1990 ). In this model, damage primarily affects hippo campal CAl neurons, which become necrotic after a de lay of 1 to 3 days. Although a similarly delayed CAl cell death is observed after forebrain ischemia in the rat, PBN failed to ameliorate the damage in that species, suggest ing species differences in pathophysiologic mechanisms (Pahlmark and Siesjo, 1996) .
NXY -059 was more efficacious than PBN. Similar results were obtained when a recovery period of 7 days was allowed. The window of therapeutic opportunity for NXY-059 was 3 to 6 hours after the start of recirculation. Studies of the transfer constant of e4C]NXY-059 showed that, in contrast to PBN, this more soluble nitrone penetrates the blood-brain barrier less extensively. This fact, and the pronounced antiischemic effect of NXY -059, suggest that the delayed events leading to infarc tion may be influenced by reactions occurring at the blood endothelial interface. Key Words: Brain damage-Free radi cals-Reperfusion-Stroke-Therapeutic window.
Recent results demonstrate, though, that PBN mark edly reduces infarct volumes in rats subjected to long periods of focal ischemia induced by middle cerebral artery (MCA) occlusion. The results emanate from ex periments on permanent distal occlusion of the MCA (Cao and Phillis, 1994) , or from transient (proximal) MCA occlusion of 2-hour duration (Zhao et a!., 1994) . In the first of these studies, infarct volume, as assessed by 2,3,5-triphenyltetrazolium chloride (TTC) staining after 2 days of occlusion, was reduced even if administration of PBN (100 mg . kg-I , 4 intraperitoneal doses, 12 hours apart) was delayed for 5 hours, with some remaining effect after 12 hours (Cao and Phillis, 1994) . In the sec ond, the window of therapeutic opportunity was 3 hours after the initiation of reperfusion (Zhao et aI., 1994) .
These results put PBN in the focus of interest, since they suggest that the nitrone acts within a therapeutic window of clinical relevance. Reperfusion after transient MCA occlusion was shown to be accompanied by an initial recovery of the bioenergetic state of focal and perifocal ("penumbral") areas, followed by secondary deterioration after 4 to 6 hours, the latter being amelio rated by PBN (Folbergrova et aI., 1995) . Studies of mi tochondrial function in vitro gave similar results, sug gesting that the secondary deterioration of the bioener-getic state was caused by mitochondrial dysfunction, which was mitigated by PBN (Kuroda et aI., 1996) . As is discussed later, it is less likely that PBN improves mi crocirculation.
We have explored the effect of a newly synthesized nitrone, NXY-059, which is more soluble than PBN, studying dose-response effects, windows of therapeutic opportunity, and recovery for 7 days with a histopatho logic endpoint. In all experiments, MCA occlusion of 2-hour duration was used. The results demonstrate that NXY -059 works within the same window of therapeutic opportunity as PBN, but is more efficacious than PBN, and can be infused to give a lasting effect at 7 days of recovery. A novel finding is that NXY-059 has this marked effect, although it turned out to be sparingly permeable through the blood-brain barrier (BBB). The implication of this finding for the pathophysiologic mechanism of focal ischemic damage is discussed here.
MATERIALS AND METHODS

Chemicals
NXY-059 (disodium 4-[(tert-butylimino)methyllbenzene-1,3-disulfonate N-oxide), a nitrone, was developed and kindly given to us by Centaur Pharmaceuticals, Inc. (Sunnyvale, CA, U.S.A.). Its chemical structure is shown in Fig. I . NRB-022 (e4ClNXY-059) (molar activity 2.2 mCi . mmol-1) was a kind gift of Astra Arcus AB (Sodertalje, Sweden). The PBN was purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.).
Animal preparation and transient middle cerebral artery occlusion
Our procedures for inducing transient MCA occlusion in anesthetized rats were as described previously (see Zhao et aI., 1994; Kuroda et aI., 1996) and are summarized here. Male Wistar rats (Mollegaard's Breeding Center, Copenhagen) were fasted overnight but had free access to water (body weight after overnight fast 300 to 345 g). Anesthesia was induced by inha-
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FIG. 1. Chemical structures of two spin trap nitrones, a-phenyl N-tert-butyl nitrone (PBN) and disodium 4-[(tert-butylimino) methyl]benzene-1,3-disulfonate N-oxide (NXY-059). lation of 3.0% halothane in N20:02 (70%:30%), and the ani mals were intubated. They were artificially ventilated with 1.0% to 1.5% halothane in N20:02 (70%:30%) during opera tion. The tail artery was cannulated to monitor arterial blood gases, pH, blood glucose, and blood pressure during surgery. A catheter also was inserted into the right jugular vein for admin istration of vehicle, PBN, or NXY-059, and then was external ized on the back of the animals at the nape of their neck. Heparin (0.1 mL, 300 units . mL -1) was given just before induction of ischemia to prevent thrombosis distal to the in serted filament. The occlusion was produced using a monofila ment fishing line (Stren Supertough, Du Pont, Wilmington, DE, U.S.A.; diameter 0.25 mm). Its tip was rounded by brief heating near an electrical heater under a surgical microscope and coated with silicon rubber (Silascon RTV-8600, Dow Corning K.K., Japan) to make a distal cylinder 0.28 mm in diameter and 5 mm in length. The right common, internal, and external carotid arteries were exposed through a ventral midline neck incision. The external carotid artery was ligated. The common carotid artery was closed by a ligature and was temporarily closed just proximal to the carotid bifurcation by a microvascular clip. A small incision was made in the common carotid artery, and the occluder filament was inserted into the internal carotid artery through the common carotid artery. The filament was advanced until a faint resistance could be felt. Length of the inserted filament was about 19 mm from the carotid bifurcation. A transient (2-to 3-minute) decrease in blood pressure was ob served. When the MCA occlusion had been performed, the animals were extubated and allowed to wake up and resume spontaneous breathing. After light reanesthesia with halothane through a face mask, the filament was withdrawn after 2 hours to allow recirculation through the circle of Willis. During the operation, an electrical temperature probe was inserted into the rectum to monitor core temperature, which was regularly main tained at 37.0° to 37.5°C using a Temperature Controller CMAI 150 (Carnegie Medicin AB, Stockholm, Sweden). During the 2-hour period of ischemia and for 2 hours after onset of reper fusion (total of 4 hours), the animals were placed in a Styro foam box in which temperature was kept between 0° and lOOC by flushing the box with air cooled by dry ice. This was per formed to avoid the hyperthermia that otherwise would occur from ischemia of hypothalamus, and to keep core temperature close to normal levels during and after MCA occlusion (see Kuroda et aI., 1996) .
Neurologic assessment
After surgery, the neurologic status of each rat was evaluated according to the neurologic grading scores described by Be derson and colleagues (Bederson et aI., 1986b) . Thus, rats that extended both forelimbs toward the floor when the animals were held up by the tail and that had no other neurologic deficit were graded O. Rats that showed consistent flexion of the left forelimb and no other abnormality when the animals were held up by the tail were graded 1. Rats that had reduced resistance to lateral push toward the left (paretic) side and gait toward the left side were graded 2. Rats that had same behavior as grade 2 and consistent circling toward the left side were graded 3.
Neurologic examination was carried out in all animals every hour during the 2-hour MCA occlusion. Only rats scoring 0 before surgery and 3 during ischemia were included in the study (Kuroda et aI., 1996) .
Experimental protocol
Our first series was performed to establish a dose-response curve for NXY-059 (0.30, 3.0, or 30 mg . kg-1 intravenous ly, followed by continuous infusion of 0.30, 3.0, or 30 mg . kg-I . h-I over 24 hours, respectively) and to compare its effect with that of PBN. In one experiment, the treatments were started I hour after the start of recirculation, after 2 hours of MCA occlusion. The results showed that infarct volume, as sessed after 2 days of recovery, was significantly reduced in a dose-dependent manner and that NXY-059 is much more effi cacious than PBN on a molar basis (see later). Therefore, the highest dose (30 mg' kg-1 intravenously and 30 mg' kg-I . h-I infusion) of NXY-059 was chosen for the subsequent experi ments. In the next series, we evaluated the window of thera peutic opportunity. Treatment with NXY-059 was started 3 or 6 hours after the start of recirculation and was continued for 24 hours. In the third series, we assessed the long-term effects of NXY-059 treatment over 48 hours on ischemic brain damage after 7 days of recovery using histopathologic techniques. In the final experiment, we evaluated the permeability of NXY-059 through the BBB using 14C-labeled drug. Notice that the solubility of this drug is different from that of PBN, which can easily pass through the BBB (Chen et a!., 1990; Cheng et a!. 1993 ).
Dose-response study of NXY -059
In this series, the animals were divided into five groups, all being allowed a recovery period of 48 hours after 2 hours of MCA occlusion. In all groups, the drug was given by bolus injection after 1 hour of recirculation and then by continuous infusion over 24 hours. For continuous infusion of the drug in awake and freely moving rats for a long time, a polyethylene tube (0.58 mm internal diameter, 0.96 mm external diameter) was inserted into the right jugular vein and externalized on the back of the animals at the nape of their neck. The drug was infused through the polyethylene tube passing through a stain less steel spring using a CMA Swivel and CMAIIOO Microin jection Pump (Carnegie Medicin AB). During continuous in fusion of the drug, the animals were allowed to move freely in their cages.
Each drug, NXY-059 or PBN, was dissolved in Krebs solu tion. The following groups were studied: 
h-I by intravenous infusion
This dose of PBN is equimolar to that of the middle-dose NXY-059 group (3.0 mg' kg-I . h-I). A control group of rats (n = 10) received an equivalent volume of Krebs solution by intravenous bolus and continuous intravenous injections. Neu rologic evaluation was performed at 24 and 48 hours of recir culation (see earlier). Infarct volume was assessed using a TTC staining technique (see later).
Window of therapeutic opportunity for NXY -059
The animals were divided into three groups and were al lowed a recovery period of 48 hours after 2 hours of MCA occlusion. In all groups, continuous infusion of Krebs solution was started at I hour of recirculation. Treated animals received 30 mg . kg-I of NXY-059 by intravenous bolus injection at 3 (n = 8) or 6 hours (n = 8) after the start of recirculation, and then 30 mg' kg-I . h-1 of NXY-059 by continuous intravenous J Cereb Blood Flow Metah, Vol. 19, No. 7, 1999 infusion for 24 hours. Control animals (n = 5) received only intravenous infusion of Krebs solution for 24 hours. Neurologic evaluations were carried out at 24 and 48 hours of recirculation (see earlier). Infarct volume was assessed after 48 hours of recovery using the TTC staining technique (see later).
Long-term study of NXY -059
The animals were divided into two groups and were allowed a recovery period of 7 days after 2 hours of MCA occlusion. In the treated group (n = 8), 30 mg' kg-I of NXY-059 was given by intravenous bolus injection at I hour of recirculation, and then 30 mg' kg-I . h-I of NXY-059 was given by continuous intravenous infusion for 48 hours, as described earlier. A con trol group of rats (n = 7) received only an equivalent volume of Krebs solution by infusion for 48 hours.
Neurologic evaluations were carried out at 2 and 7 days, respectively, of recirculation (see earlier). Infarct volume was assessed using transcardiac perfusion and conventional histo pathologic staining techniques (see later).
TTC staining
The rats were anesthetized by inhalation of 3.0% halothane in N20:02 (70%:30%) and killed by decapitation at 48 hours of recirculation, The brain was quickly removed and chilled in ice-cold saline for 10 minutes. Twelve I-mm coronal slices were cut with a tissue slicer, beginning I mm posterior to the anterior pole. The slices were immersed in a saline solution containing 1.0% TTC at 37°C for 30 minutes (Bederson et a!., 1986a) and fixed by immersion in 4.0% phosphate-buffered formalin solution. Each brain slice was photographed with black-and-white film (TMAX 100 pro, Kodak, Rochester, NY, U.S.A.), and the unstained area in each photograph was quan tified from the developed film using a CCD video camera (SPTMI24, Sony, Park Ridge, NJ, U.S.A.) and a video image analyzing system (NIH image, version 1.55). The infarct area in each slice was obtained by subtracting the area of normal tissue of the ipsilateral hemisphere from the total area of the contra lateral hemisphere to avoid overestimation of infarct volume resulting from cerebral edema in acute stage of ischemia. The total infarct volume was determined by summing the infarct areas of the 12 slices and was presented as the percentage of the infarct to the total volume of the contralateral hemisphere,
Histopathology
After 7 days of recovery, the animals were reanesthetized and artificially ventilated with 3.0% halothane in N20:02 (70%:30%). A thoracotomy was made, and a cannula was in serted into the ascending aorta through the left ventricle. The animals were transcardially perfused with heparinized saline and then with phosphate-buffered 4% formaldehyde (pH 7.4), and the brains were removed. The brain tissues were dehy drated, embedded in paraffin, sectioned coronally at 5-mm thickness, and stained with celestine blue and acid fuchsin for histopathologic evaluation.
Volumes of brain damages were measured according to Os borne and collaborators (Osborne et a!., 1987) . Coronal sec tions at 10 levels were examined, and the outlines of infarction and selective neuronal necrosis were drawn on brain maps. The areas of infarction and selective neuronal necrosis at each level were directly analyzed using a video image analyzing system (see earlier) because cerebral edema observed at 2 days of reperfusion had already disappeared. The volume (percentage of the contralateral hemisphere) of infarction, selective neuro nal necrosis, and total ischemic damage then was calculated from all sections.
Blood-brain barrier permeability study of e 4 C]NXY -059
Before experiments, C 4CjNXY-059 was mixed with nonra dioactive ("cold") NXY-059 in a 1:1 ratio to reduce its radio activity. Sixteen rats were used for this study. They were di vided into three groups. In the first group, 30 mg . kg�1 of [14CjNXY-059 (86 . Ci . kg�l) was given by intravenous bolus injection to rats subjected to sham operations 3 hours after the operation (n = 5). The other two groups of animals were allowed a recovery period of 1 (n = 5) or 4 hours (n = 6) after 2 hours of MCA occlusion. In the former, 30 mg . kg�1 of e 4CjNXY-059 was given by intravenous bolus injection 1 hour after the onset of recirculation. In the latter, 30 mg . kg�1 of cold NXY -059 was given by intravenous bolus injection I hour after the onset of recirculation, and then 30 mg . kg�1 . h� l of cold NXY -059 was continuously infused intravenously. At 4 hours of recovery, 30 mg . kg� l of [14C]NXY-059 was injected as an intravenous bolus. Uptake of [14CjNXY -059 into the brain was measured in awake animals placed in a small tube shaped Plexiglas cage, which restricted their movements. Each rat received the [ 1 4C]NXY-059 20 minutes before decapitation through the catheter placed into the tail vein. Arterial blood samples (0.05 mL) were collected in O.4-mL microcentrifuge tubes before and 0.25, 0.5, I, 2, 5, 10, and 20 minutes after injection of C4C1NXY-059. Just after sampling of the last ar terial blood, the animals were decapitated, and the brain was quickly removed. After removal of the arachnoidal membrane and subarachnoidal blood vessels, the brain was immersed in 2-methylbutan (KEBO Lab, Spanga, Sweden), which was cooled to _40DC by liquid nitrogen. The brain was kept in a deep freezer until determination of radioactivity. Arterial blood samples were centrifuged for 45 to 60 seconds (Sigma 110, Berlin, Germany) to obtain plasma. Twenty mi croliters of plasma were pi petted into vials containing 0.8 mL of a 1: 1 mixture of soluene (Packard, Groningen, The Nether lands) and isopropanol (Fluka Chemie Ab, Buchas, Germany). The following day, 3.5 mL of Ready-Safe (Beckman Instru ment, Fullerton, CA, U.S.A.) was added and the vials were mixed and left for at least 5 hours before counting. Subregions from the lateral caudoputamen, somatosensory cortex ("pen umbra"), and motor cortex ("focus") were dissected from co ronal sections of 2-mm thickness through the caudoputamen at -15°C. The brain samples were dissolved in soluene over 24 hours in room temperature and then prepared for scintillation counting together with the blood samples. Radioactivity was counted on a liquid scintillation analyzer, TRI-CARB 2100TR (Packard Instrument Company, Meriden, CT, U.S.A.).
A blood-to-brain transfer content (Kin for [14C] NXY -059) was determined according to the equation of Ohno and col leagues (1978) as follows:
where Kin is the transfer constant (f.LL . g� l . min�I), Ci (T) is the concentration of tracer in the brain at the end of the experi ment, Cb is the concentration of tracer in the residual blood in the brain at the end of the experiment, and Cp is the concen tration of tracer in the plasma. Parenchymal brain concentration (Ci) is expressed as dpm . g� l tissue minus dpm within the residual blood (Cb). We corrected for residual blood by using a factor previously determined in the laboratory.
Statistics
All values are presented as mean ± SD or the median, the 25th percentile, and the 75th percentile. For comparisons of parametric data, analysis among multiple groups were carried out by one-factor analysis of variance followed by Dunnett's test. Comparison between two groups was carried out using the unpaired t test. For comparisons of nonparametric data, analy sis among multiple groups were carried out by Kruskal-Wallis test followed by Mann-Whitney U test. Statistical significance between two groups of nonparametric data was determined using Mann-Whitney U test. Statistical significance was set at P < 0.05.
RESULTS
Physiologic parameters
There were no significant differences in arterial Pco2, Po2, pH, blood glucose, and blood pressure between the experimental groups before ischemia, except for P02 and pH in BBB permeability study of e 4 C]NXY-OS9. In the study, P02 (112.9 ± 9.7 mm Hg; P < 0.01) and pH (7.443 ± 0.0 10; P < O.OS) of the animals that received intrave nous bolus injection of [ 14 C]NXY -OS9 at 1 hour of reper fusion were significantly lower before MCA occlusion than those (133.8 ± 9.7 mm Hg and 7.477 ± 0.026, re spectively) of sham-operated animals. However, we be lieve that the differences in P02 and pH for the I-hour postdosing group would not have had any effect on the results of this study.
No significant differences between groups were ob served in core temperature throughout the experiments (Table 1) .
Dose-dependence study of NXY -059: comparison withPBN Table 2 shows the effects of treatments on neuro logic deficits at 24 and 48 hours of recirculation after 2 hours of MCA occlusion. Control rats showed severe neurologic deficits in both tests at 24 and 48 hours of recirculation, with median scores of 2.S. When the rats were treated with the low dose of NXY -OS9, they showed significantly lower scores at 24 hours (median score 1, P < 0.0001) and at 48 hours (median score O.S, P < 0.0001). When the rats were treated with the middle or the high dose of NXY -OS9, they exhibited signifi cantly lower scores, both at 24 and 48 hours. Treatment with the middle dose of NXY -OS9 attenuated the median scores to I (P = 0.0002) and 0 (P = 0.0040) at 24 and 48 hours, respectively. Treatment with the high dose of NXY -OS9 showed an even more prominent effect on neurologic deficits and reduced the median scores to o both at 24 hours and at 48 hours (P < 0.0001). In contrast, there was no significant difference of neuro logic scores between the control rats and the PBN-treated rats. Figure 2 illustrates the effects of treatments on infarct volume at 48 hours of recirculation after 2 hours of MCA occlusion. In the control rats, infarction was observed in the lateral caudoputamen and the cortex fed by the ipsi lateral MCA, the percentage of infarct volume varying from 22.9% to 49.1 % with a mean value of 35.7 ± 9.0% of the contralateral hemisphere. NXY-059 treatment sig nificantly reduced infarct volume. When the rats were treated with the low, middle, and high doses of NXY-059, infarct volume was attenuated to 17.3 ± 16.1 % (P < 0.05), 15.3 ± 12.8% (P < 0.0l), and 8.3 ± 3.7% (P < 0.01), respectively. No infarction was detected in 2 (25%) of 8 rats treated with the low dose of NXY -059, in 3 (25%) of 12 rats treated with the middle dose of NXY-059, and in 4 (50%) of 8 rats treated with the high dose of NXY-059. Treatment with PBN in a dose equimolar with the group given NXY-059 in a dose of 3.0 mg ' kg-I failed to affect infarct volume (33.7 ± 4.9%).
37.2 ± 0.2 37.9 ± 0.3 37.4 ± 0.7 37.4 ± 0. 5 37.7 ± 0.4
36.9 ± 0.3 38.0 ± 0.2 37.6 ± 0.1 37.5 ± 0.3 37.3 ± 0.2 37.3 ± 0.3 37.9 ± 0.3 37.3 ± 0.6 37.6 ± 0. Window of therapeutic opportunity for NXY -059 Table 2 shows the effects of NXY -059 on neurologic deficits at 24 and 48 hours of recirculation after 2 hours of MCA occlusion in animals with treatment delays of 3 or 6 hours. The NXY -059 significantly improved neuro logic deficits at 24 hours (median value 2, P = 0.0148) when given at 6 hours of reperfusion, but there was no significant improvement at 48 hours of reperfusion in animals with treatment delays of 3 or 6 hours. Figure 3 demonstrates the effects of NXY -059 on infarct volume at 48 hours of recirculation. In the control rats, the percentage of infarct volume varied from 27.4% to 50.7%, with a mean value of 39.7 ± 9.1 % of the contra lateral hemisphere. The NXY-059 treatment significantly reduced infarct volume when started at 3 hours of recir culation (mean 13.8 ± 15.1 %; P < 0.05), although its *Against control animals (P < 0.05), one-factor ANOVA followed by Dunnett's test.
Long-term effects of NXY -059 on brain damage Table 2 illustrates the effects of treatment with 30 mg . kg-I . h-I on neurologic deficits at 2 and 7 days, respectively, of recirculation after 2 hours of MCA oc clusion. Control rats showed severe neurologic deficits in both tests at 2 days and 7 days of recirculation, with median scores of 3. The treated rats, though, showed significantly lower scores in both tests at 2 days and 7 days of recirculation with median scores of 0 (P < 0.0 I). Figure 4 demonstrates the effects of NXY-059 on brain damage at 7 days of recovery. In all control rats, infarction and a surrounding area of selective neuronal necrosis could be observed in the lateral caudoputamen and the cortex fed by the ipsilateral MCA. Mean volumes of infarct and selective neuronal necrosis were 25.9 ± 5.2% and 3.7 ± 2.0%, respectively. As a result, the mean volume of total damage was 29.6 ± 3.6%. Treatment with NXY -059 for 48 hours significantly ameliorated the brain damage. Thus, mean volumes of infarct and total damage were decreased to 9.2 ± 14.8% (P < 0.05) and 10.9 ± 15.8% (P < 0.01), respectively.
Blood-brain barrier permeability of NXY -059
As discussed earlier, the BBB permeability of NXY-059 was determined by deriving a transfer coefficient (Kin) from the rate of influx of 14 C-Iabeled drug. As shown in Fig. 5 
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of sham-operated rats were similar (0.06 to 0.09 fLL · g-I . min-I ; Fig. SA) . Statistical analysis revealed a significant difference for the caudoputamen Kjn value for the ischemic side, compared with the contralateral side, of rats that had a 2-hour MeA occlusion and then were given a 30-mg . kg-I bolus of e 4 C]NXY-OS9 1 hour after the start of recirculation (0.14 ± 0.04 versus 0.07 ± 0.02 fLL . g-I . min-I ; P < 0.01). However, there was no significant difference of Kjn values in other subregions of animals that had undergone MeA occlusion and were injected with the isotope at either 1 hour (Fig. SB) or 4 hours (Fig. SC) after the start of recirculation.
DISCUSSION
Protective effects of PBN and NXY -059
The intraluminal filament technique is widely recog nized as a reliable model of focal ischemia, suitable for reperfusion studies. In the current study, transient MeA occlusion induced reproducible damage in the lateral caudoputamen and the overlying cortex in control ani mals after recovery for 2 days (3S.7 ± 9.0% of the con tralateral hemisphere) and for 7 days (29.6 ± 3.6%). Pre vious data from our laboratory showed that 100 mg . kg-I of PBN markedly reduced infarct volume after 2 days of recovery, even when given by bolus intraper itoneal injection 1 or 3 hours after recirculation (Zhao et aI., 1994) . Subsequent studies showed that the same dose of PBN prevented secondary deterioration of the bioen ergetic state and of mitochondrial dysfunction when given 1 hour after recirculation (Folbergrova et aI., 1995; Kuroda et aI., 1996) .
Whether this reflects an effect of PBN on the ad equacy of cerebral circulation remains a matter of debate. Schulz and coworkers (1997) , who treated animals with PBN before and during 90 minutes of MeA occlusion, conclude from their Doppler flow and magnetic reso nance imaging data that PBN reduces infarct volume by improving postischemic blood flow in the first 1 to 2 hours of reperfusion. Their result is at variance with those obtained with 14 C-iodoantipyrine autoradiography (Tsuchidate et aI., 1997) ; besides, it is not consistent with other results from our laboratory in which the laser Doppler flow technique was used to measure erythrocyte velocity, or microelectrodes were used to measure tissue P02 (Nakai et aI., 1997) . Furthermore, using a double staining technique, we have been unable to show that 2 hours of MCA occlusion reduces capillary patency dur ing recirculation (Li et aI., 1998) . All of these results favor the view that microcirculatory dysfunction is not the reason why secondary bioenergetic failure is ob served in the first 4 hours of reperfusion, and they iden tify mitochondrial dysfunction as the most important pathogenetic event.
These studies suggest that reactive oxygen species (ROS) are important mediators of reperfusion injury and that mitochondria constitute a major target of ROS. o:-Phenyl-N-tert-butyl nitrone has been known to rapidly react with free radicals, yielding a relatively stable ni troxide free radical (Floyd, 1990) . Clearly, compounds of the class to which PBN belongs are interesting from a clinical perspective. Despite its interesting antiischemic effects, PBN is not an ideal nitrone because three intra peritoneal injections of 100 mg . kg-I of PBN, the first given at I hour after the start of recirculation, postpones rather than prevents damage from 2-hour MCA occlu sion. Thus, this dosing gave a marked reduction in infarct size when the latter was evaluated after 2 days of recov ery (Zhao et aI., 1994) but a less pronounced one when recovery was extended to 7 days (Zhao, Smith, and Siesjo, unpublished data) .
Our work with the more soluble nitrone (NXY -OS9) was inspired by these considerations (and findings). This nitrone could be infused intravenously over 24 or 48 hours in doses of 30 mg . kg-I . h-I (or higher) with no untoward effects. Four aspects of the results were notice able. First, NXY-OS9 reduced in a dose-dependent man ner the infarct volume, as evaluated by TTC staining after 2 days of recovery (Fig. 2) . Neurologic symptoms also improved at 24 and 48 hours of recovery in a dose dependent manner. Second, the therapeutic window for NXY-OS9 was as wide as that for PBN. Thus, infarct volume decreased to 8.3 ± 3.7% (P < 0.01) when treat ment was started 1 hour after recirculation, to 13.8 ± IS.l% (P < O.OS) when started at 3 hours, but did not decrease when started at 6 hours (see Fig. 2 and 4) . However, neurologic symptoms did not show significant improvements at 48 hours of recovery when treatment was started at 3 or 6 hours of recovery. It is not clear why neurologic symptoms transiently improved at 24 hours, but not at 48 hours, when treated at 6 hours in compari son with controls (Table 2) . Third, at equimolar doses (3.0 mg . kg-1 for NXY-OS9), NXY-OS9 was more effi-cacious than PBN (Fig. 2) . Fourth, when the compound was infused for 48 hours in a dose of 30 mg . kg-I . h-I , a marked reduction in infarct size also was observed after 7 days of recovery with a histopathologic endpoint (Fig.  4) . Remember that in all experiments within I hour after treatment, amelioration of tissue damage was paralleled by an improvement of neurologic status. These findings suggest that NXY-OS9 has more potent actions on reper fusion injury after focal ischemia than PBN, and that NXY -OS9 could become clinically important because the drug has a high solubility in water, a wide therapeutic window, and long-lasting effects. However, the results obtained with NXY-OS9 raise some novel aspects of pathophysiologic events involved in infarct develop ment. Thus, the compound had a marked antiischemic effect, although its penetration through the BBB at 1 or 4 hours was low; in fact, the Kin value obtained is as low as that previously measured for sucrose and molecules considered to be virtually excluded from entering the brain (see Ohno et a!., 1978) . This finding indicates the possibility that the effects of NXY-OS9 are exerted at processes occurring at the blood-endothelial cell inter face.
It is not known why NXY-OS9, which has a similar efficacy as PBN in trapping oxygen-and carbon centered radicals, is more effective than PBN as an an tiischemic agent. Data obtained at Centaur Pharmaceu ticals in nonischemic rats allow approximations to be made with respect to doses versus steady-state plasma levels. Thus, at NXY-OS9 doses of 0.3, 3.0, and 30 mg . kg-I . h-\ the steady-state plasma levels can be approximated to O.S, S, and SO f.Lg . mL-1 , or l.3, 13, and 130 f.Lm, respectively. Infusion of PBN at a dose of 1.4 mg . kg-I . h-I is expected to give a steady-state plasma level of 8.6 f.Lg . mL -I (49 f.Lmol). Thus, although the dose of PBN was equimolar to that of NXY -OS9, the exposure to PBN was threefold to fourfold greater, prob ably because PBN has a much slower clearance rate than NXY-OS9. In view of this, it seems unlikely that PBN is less efficacious than NXY -OS9 because PBN attains lower concentrations in the vascular bed than NXY-OS9.
Possible mechanisms of NXY -059
Studies demonstrate that mitochondria are important intracellular sources of ROS under pathologic conditions such as exposure to glutamate or ischemia-reperfusion (Piantadosi and Zhang, 1996) . Neuronal nitric oxide syn thase is also known to contribute to intracellular produc tion of ROS (Dawson, 1994) . As remarked, PBN can easily pass through the BBB and distribute in the brain because of its lipophilic character. Thus, the brain con centration of PBN reaches its peak 20 minutes after in jection and then decreases slowly, and is significantly higher than that in blood (Chen et aI., 1990; Cheng et a!., 1993) . Therefore, PBN seems to rapidly react with ROS in the brain and attenuate ROS-mediated tissue damage during reperfusion.
However, the current study reveals that NXY -059 can not easily pass through the BBB, probably because of its high solubility in water. Other extracellular sources of ROS should, therefore, be considered to explain why NXY -059 showed dramatic protective effects against reperfusion injury. The interactions between endothelial cells and inflammatory cells, such as polymorphonuclear (PMN) leukocytes and macrophages, are believed to be potent extracellular sources of ROS during reperfusion (Betz, 1996; Hallenbeck, 1996) . Once activated, these inflammatory cells can generate superoxide anions (02'-) and hydrogen peroxide (H202), which may react to give the highly reactive hydroxyl radical (·OH). These cells also can generate nitric oxide (NO), which reacts with superoxide to yield the peroxynitrite anion through the action of inducible NO synthase. The peroxynitrite anion itself is a highly reactive oxidant that can cause tissue damage but also can decompose to yield ·OH (Beckman et aI., 1996) . It is becoming increasingly clear that the upregulation of adhesion molecules on the sur face of the endothelial cells and on the inflammatory cells is essential to the involvement of these cells in reperfusion injury (del Zoppo, 1994; Betz, 1996; Hallen beck, 1996) . Adhesion molecules such as the intercellu lar adhesion molecule-l can be detected on the endothe lial cells during the early phase (l to 4 hours) of reper fusion after transient MeA occlusion. The PMN leukocytes start to accumulate in the tissue much later, that is, 12 to 24 hours after recirculation. Other studies demonstrate increased activities of myeloperoxidase and inducible NO synthase (Iadecola and Ross, 1997) during this later phase of reperfusion. Matsuo and collaborators directly showed that the circulating PMN leukocytes are a major source of "extracellular" ROS in the early (1-to 2-hour) phase of reperfusion after focal ischemia and that infiltrating PMN leukocytes contribute to ROS produc tion in its late (24-hour) phase (Matsuo et aI., 1995) . It is thus possible that focal ischemic damage can be amelio rated by drugs that only sparingly pass the BBB (Siesjo and Siesjo, 1996) .
Furthermore, it has been shown that endothelial cells have high concentrations of mitochondria, polyunsatu rated fatty acids, and xanthine oxidase and that they also are potent generators of ROS. Thus, it has been shown that cultured endothelium can generate 'OH and NO dur ing anoxia-reoxygenation (Kumar et aI., 1996) . These findings strongly suggest that NXY -059 may attenuate ROS-mediated reperfusion injury by interfering with the interaction between inflammatory cells and the endothe lium, or by directly reacting with ROS produced by cir culating inflammatory cells or the endothelium.
In summary, we conclude from the current study that the novel nitrone, NXY-059, is a potent neuroprotective J Cereb Blood Flow Metab. Vol. 19. No.7. 1999 drug that has a wide window of therapeutic opportunity and a long-lasting effect on reperfusion injury after focal ischemia. The neuroprotective effect of NXY -059 is pos sibly related to its ability to yield adducts of ROS or other free radicals that are generated through the inflam matory or immunologic reaction, which is most clearly elicited during reperfusion after focal ischemia (Hallen beck, 1996) .
